Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07673744 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Jul 30, 2026 to Oct 1, 2026 Study sites: 5 to 6 · Eligibility criteria expanded, about 9 words · Secondary endpoints: details revised at 1 of 4 entries Show 3 more changesShow less
    • Study sites: 5 to 6
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 1 of 4 entries
  2. Trial sites expanded: 2 → 5 locationsv3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary purpose of this study is to evaluate the efficacy of ublituximab in adult participants with MG responding to treatment with efgartigimod.
Trial Details
NCT Number NCT07673744
Lead Sponsor TG Therapeutics, Inc.
Conditions Myasthenia Gravis
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov